secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255167
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23
-----------------------------------------------------------------

- GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
- Adjusted gross margin 50.7%; adjusted operating margin 14.9% vs 3.7%.
- Full-year 2024 revenue guidance narrowed to $630-$639M (midpoint unchanged).
- CDMO revenue and orders each grew ~20% YoY; new modalities record quarterly revenue.
- Announced definitive agreement to acquire chromatography firm Tantti Laboratory Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/0001193125-24-255167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/d811195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer